Trends in Molecular Medicine

Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?
pp. 195-197(3)
Authors: Taylor J.P.; Fischbeck K.H.

Healing a natural knockout of epithelial organogenesis
pp. 197-200(4)
Authors: Kere J.; Elomaa O.

Molecular goings on in Down's syndrome
pp. 201-202(2)
Author: Isles A.

Embryonic stem cells as treatment of Parkinson's disease: so near and yet so far
pp. 201-201(1)
Authors: Dubois-Dauphin M.; Krause K.-H.

Antisense peptides designed to inhibit -amyloid aggregation
pp. 202-202(1)
Author: Cuccia L.

Abl to autoinhibit
pp. 202-203(2)
Author: Weitzman J.B.

In brief
pp. 203-204(2)
Authors: Weitzman J.; O'Neill P.

Connexin mutations in hearing loss, dermatological and neurological disorders
pp. 205-212(8)
Authors: Rabionet R.; Lopez-Bigas N.; Arbones M.L.; Estivill X.

Triggering caspase-independent cell death to combat cancer
pp. 212-220(9)
Authors: Mathiasen I.S.; Jaattela M.

Molecular insights into Friedreich's ataxia and antioxidant-based therapies
pp. 221-224(4)
Authors: Rotig A.; Sidi D.; Munnich A.; Rustin P.

Immunotherapy with ligands of natural killer T cells
pp. 225-231(7)
Authors: Wilson M.T.; Singh A.K.; Van Kaer L.

The role of chaperones in polyglutamine disease
pp. 232-236(5)
Authors: Opal P.; Zoghbi H.Y.

Parkinson's disease: one biochemical pathway to fit all genes?
pp. 236-240(5)
Authors: Kruger R.; Eberhardt O.; Riess O.; Schulz J.B.; Riess O.

Getting under the skin of melanoma
pp. 241-242(2)
Author: Tsao H.

Inflamed in the brain
pp. 241-241(1)
Author: O'Banion M.K.

Beware of paradigms
pp. 242-243(2)
Author: Alizon M.

Cancer biology for the clinic and the lab
pp. 242-242(1)
Author: Eisen T.

Angiogenesis assays
pp. 243-243(1)
Author: Auerbach R.

Corrigendum
pp. 243-243(1)
Authors: Herrera R.; Sebolt-Leopold J.S.